Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behcet's disease uveitis

Next Previous
X
Search
Trial Profile

A randomised, double-masked, placebo-controlled study of the efficacy of gevokizumab in the treatment of patients with Behcet's disease uveitis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gevokizumab (Primary)
  • Indications Behcet's syndrome; Uveitis
  • Focus Registrational; Therapeutic Use
  • Acronyms EYEGUARD-B
  • Sponsors Servier

    • Most Recent Events

    • 05 Oct 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 22 Jul 2015 According to a Xoma media release, this trial enrolled a total of 83 patients in the core part of the study (40 on gevokizumab and 43 on placebo). Patients were randomized when they reached the step of 20 mg/day equivalent oral prednisone and continued a standardized tapering regimen until they reached 5 mg/day during double-masked treatment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top